MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Proceeds from maturitiesand sales of...$1,033,259K Net proceeds fromstock option...$8,676K Net cash provided byinvesting activities$377,184K Net cash provided byfinancing activities$8,676K Canceled cashflow$656,075K Net change in cashand cash...$12,883K Canceled cashflow$372,977K Purchases of marketablesecurities$641,759K Payments associated withlicense agreement$10,000K Purchases of property andequipment$4,316K Stock-based compensationexpense$52,552K Non-cash operating leaseexpense$12,425K Expense associated withlicense agreement$10,000K Depreciation andamortization$5,177K Accounts payable$1,746K Loss (gain) ondisposal of property and...-$5K Net cash used inoperating activities-$372,977K Canceled cashflow$81,905K Net (loss) income-$412,781K Operating leaseliabilities-$16,781K Net accretion ofdiscount on marketable...$7,195K Accounts receivable, net$6,468K Inventory$5,304K Prepaid expenses andother current and...$3,172K Accrued expenses-$1,402K Income taxes payable-$871K Other liabilities-$790K Realized gain oninvestments$118K
Cash Flow
source: myfinsight.com

AGIOS PHARMACEUTICALS, INC. (AGIO)

AGIOS PHARMACEUTICALS, INC. (AGIO)